Daebongls.Co.,Ltd.

A078140

KR7078140001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
11,020 ^KRW	-2.65%		+1.47%	+20.31%

May. 16	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Daebongls.Co.,Ltd. authorizes a Buyback Plan.

February 25, 2021

The Board of Directors of Daebongls.Co.,Ltd. has authorized a buyback plan on February 26, 2021.

Latest news about Daebongls.Co.,Ltd.

Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021.	21-06-04	CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021.	21-06-04	CI
Daebongls.Co.,Ltd.’s Equity Buyback announced on February 26, 2021, has expired with 61,995 shares, representing 0.56% for KRW 616.17 million.	21-05-31	CI
Daebongls.Co.,Ltd. announces an Equity Buyback for 100,000 shares, for KRW 986 million.	21-02-26	CI
Daebongls.Co.,Ltd. authorizes a Buyback Plan.	21-02-25	CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	20-10-05	CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	20-10-05	CI
Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	20-10-05	CI
Daebongls.Co.,Ltd.’s Equity Buyback announced on April 3, 2020, has expired with 76,415 shares, representing 0.69% for KRW 727.29 million.	20-10-04	CI
P&K Skin Research Center Co., Ltd. has completed an IPO in the amount of KRW 40.8639 billion.	20-09-04	CI
P&K Skin Research Center Co., Ltd. has filed an IPO.	20-04-28	CI
Daebongls.Co.,Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares.	20-04-02	CI
Daebongls.Co.,Ltd. authorizes a Buyback Plan.	20-04-02	CI

Daebongls. Co., Ltd. is a Korea-based company engaged in the manufacture of raw materials for pharmaceuticals and cosmetics. The Company operates its business through two main divisions: cosmetic division, which provides aloe vera gels, beta carotens, calamines, diaformers, emulgades and others for conditioners, emulsifiers, emollients, polymers, thickeners and others; pharmaceutical division, which provides almagates, bentonites, calcitriols, erdosteines, fish oil and others for antibiotics, cough products, expectorants and others. In addition, it is involved in the provision of food chemical additives, fish feedstuff and others. The Company distributes its products within domestic market and to overseas markets, including Japan, America and other Southeast Asian countries.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAEBONGLS.CO.,LTD.	+20.31%	88.34M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B